Get the Stockscreener App
1.13
2.73%
0.03
Pre-market:
1.13
Eyenovia Inc stock is traded at $1.13, with a volume of 28,130.
It is up +2.73% in the last 24 hours and down -33.14% over the past month.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
See More
Previous Close:
$1.10
Open:
$1.07
24h Volume:
28,130
Relative Volume:
0.07
Market Cap:
$2.37M
Revenue:
$31,800
Net Income/Loss:
$-37.83M
P/E Ratio:
-1.5915
EPS:
-0.71
Net Cash Flow:
$-30.64M
1W Performance:
-15.04%
1M Performance:
-33.14%
6M Performance:
-97.20%
1Y Performance:
-98.56%
1-Day Range:
$1.06
$1.13
1-Week Range:
$1.0563
$1.34
52-Week Range:
$1.0563
$124.80
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Compare EYEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
1.13 | 2.37M | 31,800 | -37.83M | -30.64M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia Inc expected to post a loss of $7.20 a shareEarnings Preview - TradingView
Eyenovia Delays Yearly Report Filing - TipRanks
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Eyenovia falls on plans to seek reverse merger - MSN
Eyenovia Enters Into Non-Binding Letter of Intent to Effect Reverse Merger With Betaliq - VisionMonday.com
Eyenovia And Betaliq Announce Potential Reverse Merger - Nasdaq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks - Yahoo Finance
Eyenovia stock falls on reverse merger plans (EYEN:NASDAQ) - Seeking Alpha
Eyenovia falls after plans to merge with private firm Betaliq - TradingView
Eyenovia Plans All-Stock Reverse Merger With Betaliq - MarketWatch
Eyenovia and Betaliq Explore Merger to Form New Ophthalmic Company Combining Innovative Drug Delivery Technologies for Glaucoma Treatment - Nasdaq
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq - GlobeNewswire
Strategic Merger Alert: Eyenovia and Betaliq Join Forces to Revolutionize Eye Care Delivery - StockTitan
EYENOVIA Earnings Preview: Recent $EYEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Eyenovia, Inc. to Host Earnings Call - ACCESS Newswire
Eyenovia regains compliance with Nasdaq - MSN
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements - GlobeNewswire
Eyenovia Shares Surge After Regaining Nasdaq Compliance: What's Going On? - Benzinga
Eyenovia regains Nasdaq compliance, eyes strategic options By Investing.com - Investing.com Canada
Eyenovia regains Nasdaq compliance, eyes strategic options - Investing.com India
Eyenovia shareholders approve reverse stock split and additional stock reserve - MSN
Eyenovia Escapes Delisting Threat: What's Next for the Optejet Developer? - StockTitan
Eyenovia regains Nasdaq compliance with stock bid price By Investing.com - Investing.com Australia
Eyenovia regains Nasdaq compliance with stock bid price - Investing.com
Eyenovia, Inc. Announces Debt Restructuring, Including Amendment to Senior Secured Debt to Improve Liquidity - Vision Monday
Eyenovia defers debt payments to bolster liquidity By Investing.com - Investing.com Nigeria
Eyenovia announces debt restructuring, improving cash runway - MSN
Eyenovia, Inc. Announces Debt Restructuring Including - GlobeNewswire
Eyenovia defers loan payments, may convert debt to equity By Investing.com - Investing.com Canada
Eyenovia defers loan payments, may convert debt to equity - Investing.com India
Eyenovia defers debt payments to bolster liquidity - Investing.com India
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives - The Manila Times
Eyenovia, Inc. Announces Amendment to Senior Secured Convertible Debt to Enhance Liquidity and Support Optejet® Development - Nasdaq
Can This Biotech's Debt Restructuring Lead to a Strategic Sale? - StockTitan
FY2025 EPS Estimates for Eyenovia Boosted by HC Wainwright - Defense World
Eyenovia Inc’s (EYEN) Stock: A -58.29% Simple Moving Average for the Past 20 Days - The News Heater
Wainwright maintains neutral Eyenovia stock, $2 target - MSN
Wainwright maintains neutral Eyenovia stock, $2 target By Investing.com - Investing.com Canada
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - GlobeNewswire
The Attractiveness of Investing In Eyenovia Inc (EYEN) is Growing - Knox Daily
Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - Marketscreener.com
Revolutionary Eye Drop Spray Shows Perfect Precision: Eyenovia's Game-Changing Solution for Millions - StockTitan
Eyenovia, Inc. Advances Development of User-Filled Optejet Device for Enhanced Ophthalmic Treatment - Nasdaq
Eyenovia enacts reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Eyenovia enacts reverse stock split to meet Nasdaq requirements - Investing.com
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):